Virinchi

- Healthcare business showing rapid growth with positive EBITDA, EBIT, and cash flows sufficient to service debt independently. - IT Products segment expected to sustain industry growth rates of about 5-7%, with ongoing SaaS business growing at ~5-6% annually. - IT Services revenue has stabilized despite previous declines due to visa regime issues; expected to maintain current levels with no further decline. - Potential for higher growth if large new client deals materialize in IT Products. - Healthcare segment aims to increase bed utilization from current 30% to 60% over a few years, potentially doubling revenue. - Oncology block expansion planned (~100 beds, Rs. 40 crore CAPEX) dependent on raising incremental capital. - Overall EBITDA and profit margins expected to improve with business stabilization and additions. - Operating cash flows in FY19 were Rs. 80 crores; expected to improve for debt servicing and controlled CAPEX going forward.

The transcript does not explicitly provide specific details on the current or expected order book or pending orders for Virinchi Limited. However, some related insights can be inferred: - The company is in discussions with a large potential client on the IT product side, which could significantly boost revenues once closed. - Additionally, talks are ongoing with smaller customers (30 to 50 store clients) in the product segment. - IT services revenues are expected to stabilize, albeit with challenges due to visa issues. - Healthcare business is expanding with plans for an oncology block; overall hospital bed capacity is growing. - No concrete order book numbers or pending orders quantified in the transcript. Therefore, while growth opportunities exist through client acquisitions, exact current or expected order bookings are not disclosed in the available information.

- Currently, Virinchi Limited is focused on reducing existing debt and using operating cash flows primarily to service principal and interest on existing loans. - The company is not planning aggressive equity or debt fundraising immediately but is considering raising fresh outside capital to fund growth, particularly for the vCard product. - Healthcare expansion, such as the oncology block with a planned CAPEX of about Rs. 40 crores, will be undertaken only if incremental capital is raised, likely through private equity. - Discussions around restructuring the business and potential strategic growth are ongoing, including possibly raising venture capital for product scalability. - Promoters intend to buy more shares post-April 2020, indicating confidence but no direct new equity issuance announced. - Overall, fresh fundraising seems targeted and linked to specific expansions or scaling products, not broad immediate capital raising.

- Oncology block at healthcare facility: About 100 beds, CAPEX ~ Rs. 40 crores; timing dependent on capital raising and stabilization. - Economy block expansion: 50 beds added recently, part of total 600 beds planned at Banjara Hills campus. - Potential small CAPEX in vCard product development (mainly salaries, third-party licenses), with some capitalization. - Healthcare general bed expansion CAPEX currently on hold, except oncology. - IT product side CAPEX primarily for product development and client requests. - Overall FY20 CAPEX ~ Rs. 25 crores, mostly IT products. - Future expansions, including other hospitals (e.g., Chennai), contingent upon raising private equity. - Promoters intend to buy back shares after April 2020, indicating strategic investment interest.

- IT Products: Expected to grow at industry rates of 5-7% annually, with efforts to acquire large clients potentially increasing growth beyond this range. - IT Services: Revenue expected to stabilize at current levels (~Rs. 56-58 crores per year) after visa-related challenges; no further decline anticipated, growth likely to return in about a year. - Healthcare: Current occupancy at ~30%, targeting ~60% utilization in a few years, implying potential doubling of healthcare revenues. Oncology block addition (100 beds) planned, expanding capacity and revenue potential. - vCard Business: Early stage growth with 500 cards in circulation; scaling up expected especially after adding NBFC lending partners to improve funnel and conversion rates. - Overall: Consolidation stage with healthier business models; positive EBITDA and cash flows targeted for debt servicing and sustained growth.